|Table of Contents|

Expression and clinical significance of pmTOR and 4EBP1 proteins in peripheral blood of patients with chronic lymphoblastic leukemia

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 22
Page:
4225-4228
Research Field:
Publishing date:

Info

Title:
Expression and clinical significance of pmTOR and 4EBP1 proteins in peripheral blood of patients with chronic lymphoblastic leukemia
Author(s):
ZENG Xuejiao1; Xierenguli Alimu1; ZHANG Manxu1; QU Jianhua1; 2
1.Hematology Center,the First Affiliated Hospital of Xinjiang Medical University,Xinjiang Urumqi 830054,China;2.Xinjiang Uygur Autonomous Region Institute of Hematology,Xinjiang Urumqi 830054,China.
Keywords:
AKT-mTOR; 4EBP1; chronic lymphoblastic leukemia
PACS:
R733.32
DOI:
10.3969/j.issn.1672-4992.2023.22.024
Abstract:
Objective:To investigate the expression and clinical significance of phosphorylated mTOR protein （pmTOR） and downstream specific transcription factor (4EBP1) in peripheral blood of patients with chronic lymphoblastic leukemia (CLL).Methods:30 newly diagnosed CLL patients were randomly selected from the hematology center of our hospital.Peripheral blood samples were collected before and after first therapy as initial group and treatment group,and 20 healthy volunteers were collected as control group.The expression of pmTOR and 4EBP1 mRNA in peripheral blood mononuclear cells was detected by qPCR,and the expression of pmTOR and 4EBP1 protein in peripheral blood mononuclear cells was detected by Western blot.Results:The relative expressions of pmTOR and 4EBP1 mRNA in the initial group were significantly higher than those in the treatment group and the control group(P<0.05),the expressions of treatment group higher than the control group(P<0.05).There was a positive correlation between pmTOR and 4EBP1 mRNA expression and protein expression in the initial group(P<0.05).The relative expression of pmTOR and 4EBP1 in high and extremely high and medium risk groups were higher than that in low risk group(P<0.05),and the expression of pmTOR and 4EBP1 in high and extremely high risk group was higher than that in medium risk group (P<0.05).Conclusion:There is an increase in the expression of pmTOR and 4EBP1 in CLL and is related to the risk of CLL.pmTOR and 4EBP1 are expected to be unique markers for clinical diagnosis and treatment of CLL and prognosis.

References:

［1］ZOU Z,TAO T,LI H,et al.mTOR signaling pathway and mTOR inhibitors in cancer:progress and challenges［J］.Cell Biosci,2020,10:31.
［2］中华医学会血液学分会白血病淋巴瘤学组，中国抗癌协会血液肿瘤专业委员会，中国慢性淋巴细胞白血病工作组.中国慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的诊断与治疗指南（2018年版）［J］.中华血液学杂志，2018,39(5):353-358. Leukemia and Lymphomatology Group of Hematology Branch of Chinese Medical Association,Hematological Oncology Professional Committee of China Anti-Cancer Association,Chinese working Group on chronic Lymphoblastic Leukemia.Guidelines for diagnosis and treatment of chronic lymphoblastic leukemia/small lymphocytic lymphoma in China(2018)［J］.Chinese Journal of Hematology,2018,39(5):353-358.
［3］MURUGAN AK.mTOR:Role in cancer,metastasis and drug resistance［J］.Semin Cancer Biol，2019,59:92-111.
［4］QIU W,REN M,WANG C,et al.The clinicopathological and prognostic significance of mTOR and p-mTOR expression in patients with non-small cell lung cancer:A meta-analysis［J］.Medicine (Baltimore)，2022,101(51):e32340.
［5］HALLEK M,SHANAFEL TD,EICHHORST B.Chronic lymphocytic leukaemia［J］.Lancet，2018,391(10129):1524-1537.
［6］沙业钦，沈晖，吴微,等.四种预后评分系统在早期无症状慢性淋巴细胞白血病患者中评估价值比较［J］.中华血液学杂志，2021,42(10):834-839. SHA YQ,SHEN H,WU W,et al.Comparison of four prognostic scoring systems in patients with early asymptomatic chronic lymphoblastic leukemia［J］.Chinese Journal of Hematology,2021,42(10):834-839.
［7］SUTO T,KARONITSCH T.The immunobiology of mTOR in autoimmunity［J］.J Autoimmun,2020,110:102373.
［8］LEE H.Phosphorylated mTOR Expression profiles in human normal and carcinoma tissues［J］.Dis Markers,2017,10:e1397063.
［9］ZHANG W,ZHOU Q,WEI Y,et al.The exosome-mediated PI3k/Akt/mTOR signaling pathway in cervical cancer［J］.Int J Clin Exp Pathol,2019,12(7):2474-2484.
［10］KARACHALIOU N,CODONY-SERVAT J,TEIXIDO C,et al.BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer［J］.Sci Rep,2015,5:17499.
［11］TAN AC.Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC)［J］.Thorac Cancer,2020,11(3):511-518.
［12］NEPSTAD I,HATFIELD KJ,GRONNINGSATER IS,et al.The PI3K-Akt-mTOR signaling pathway inhuman acute myeloid leukemia (AML) cells［J］.Int J Mol Sci,2020,21(8):2907.
［13］LEE BJ,BOYER JA,BURNETT GL,et al.Author correction:Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth［J］.Nat Chem Biol,2021,17(11):1209.
［14］YU G,HUANG B,CHEN G,et al.Phosphatidylethanolamine-binding protein 4 promotes lung cancer cells proliferation and invasion via PI3K/Akt/mTOR axis［J］.J Thorac Dis,2015,7(10):1806-1816.
［15］ZHANG T,GUO J,LI H,et al.Meta-analysis of the prognostic value of p-4EBP1 in human malignancies［J］.Oncotarget,2017,9(2):2761-2769.
［16］DU KP,LIU JW,LIU CS,et al.A multi-omics pan-cancer analysis of 4EBP1 in cancer prognosis and cancer-associated fibroblasts infiltration［J］.Front Genet,2022,13:845751.
［17］CHEN BN,SONG Y,ZHAN YJ,et al.Fangchinoline inhibits non-small cell lung cancer metastasis by reversing epithelial-mesenchymal transition and suppressing the cytosolic ROS-related Akt-mTOR signaling pathway［J］.Cancer Lett,2022，543:215783.
［18］ALABDULLAH ML,AHMAD DA,MOSELEY P,et al.The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer［J］.J Obstet Gynaecol,2019,39(4):522-528.
［19］BROWN JR,BYRD JC,COUTRE SE,et al.Idelalisib,an inhibitor of phos-phatidylinositol 3-kinase p110delta,for relapsed/refractory chronic lymphocytic leukemia［J］.Blood,2014,123(22):3390-3397.
［20］ALQURASHI N,HASHIMI SM,ALOWAIDI F,et al.Dual mTOR/PI3K inhibitor NVP-BEZ235 arrests colorectal cancer cell growth and displays differential inhibition of 4E-BP1［J］.Oncol Rep,2018,40(2):1083-1092．

Memo

Memo:
National Natural Science Foundation of China(No.81860033,82160034);国家自然科学基金项目（编号：81860033,82160034）；新疆维吾尔族自治区科技计划项目（编号：2022D14008）
Last Update: 1900-01-01